Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the […]
Women’s Health & the Microbiome Women’s health refers to a collection of conditions experienced exclusively by women such as pregnancy or menopause, or experienced differently by women than men, such as heart disease and anxiety. […]
LBPs represent a paradigm shift in the approach to healthcare. Unlike traditional pharmaceuticals, LBPs harness the power of live microorganisms to influence and rebalance the intricate mechanisms of the microbiome within the body. Their impact […]
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC., a microbiome health ingredient company whose mission is to improve human health, […]
Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment […]
Researchers from University of California San Diego, as part of a large collaboration with scientists around the world, have developed a new search tool to help researchers better understand the metabolism of microorganisms. Microbes are […]
Researchers at APC Microbiome Ireland (APC), a world-leading SFI research centre based in University College Cork (UCC), have made a world-first discovery in the role the human virome plays in stress management. The findings support […]
Introduction Twenty twenty three marked a difficult year for the entire biopharmaceutical sector, with reduced funding across the field. Despite this difficulty, microbiome drug development companies became more creative and collaborative than ever, with partnership […]
International research led by the Translational Synthetic Biology Laboratory of the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University has succeeded in efficiently engineering Cutibacterium acnes -a type of skin bacterium- to produce and secrete a […]
AOBiome Therapeutics Inc. (“AOB”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s […]
The European Investment Bank (EIB) has signed a €20 million venture debt financing agreement with The Akkermansia Company, a Belgian company specialising in microbiome health, backed by the European Commission’s InvestEU initiative. Started as a spin-off […]